Spanish Grifols SA, the top Europe blood products manufacturer, agree to acquire Talecris Biotherapeutics in about $3.4 billion, or $19 cash per share, as well as 0.64 shares for each new Talecris papers.

Japanese Astellas Pharma Inc. said their offer for OSI Pharmaceuticals is final, although the Food and Drug Administration recently approved OSI´s lead drug, Tarceva (Erlotinib)to treat initial non-small cell lung cancer.

California-based Biotechnology Cougar Biotechnology Board of Directors recommended to share holders to accept J&J offer of 43 dollars per paper.

It appears ImClone Systems Inc. wants to continue being the star of the industry news these days: the biotech has now announced that by October 1st, it expects either a solid purchase proposal or formal rejection from the unnamed company interested in acquiring the biotech, according to ImClone, at $ 70 per share. Into the picture too now comes European partner Merck KGaA, which says it could consider taking part in a potential bid.

Roche Holding AG proposal to acquire the shares of Genentech it does not already own "substantially undervalues the company", said the South San Francisco-based biotechnology in a statment. Genentech formed a special committee to review the $ 43.7 billion proposal last month.

Vaccine developer VGX and electroporation specialist Inovio Biomedical penned a merger agreement in July 2008 and believe the merger will bolster their DNA vaccine pipeline, by combining Inovio’s electroporation technology with VGX’s Cellectra delivery platform

Japan´s Takeda Pharmaceutical Co.and U.S. drugmaker Abbott Laboratories are in the final stages of negotiations for Takeda to buy Abbot´s 50 percent stake in their U.S. joint venture, TAP Pharmaceutical Products Inc.. Half of the Illinois-based joint venture stake is estimated to be worth 5 billion dollars.

Swiss Galderma Pharma will acquire CollaGenex for approximately $420 million, enhancing its porfolio. CollaGenex will bring Oracea(R), the first FDA-approved product for rosacea, and its experimental Col-118, for the treatment of erythema